Fimepinostat, also known as CUDC-907, is a dual PI3K and HDAC inhibitor. Fimepinostat is able to enhance antitumor activity when combined with standard of care agents to inhibits cell growth in a wide variety of malignances. Reagent grade, for research purpose.
Usually ships within 24 hours.